Novartis AG Gross Profit 2010-2022 | NVS

Novartis AG annual/quarterly gross profit history and growth rate from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Novartis AG gross profit for the quarter ending March 31, 2022 was $8.958B, a 3.5% increase year-over-year.
  • Novartis AG gross profit for the twelve months ending March 31, 2022 was $37.313B, a 8.32% increase year-over-year.
  • Novartis AG annual gross profit for 2021 was $37.01B, a 6.42% increase from 2020.
  • Novartis AG annual gross profit for 2020 was $34.777B, a 1.53% increase from 2019.
  • Novartis AG annual gross profit for 2019 was $34.252B, a 8.43% increase from 2018.
Novartis AG Annual Gross Profit
(Millions of US $)
2021 $37,010
2020 $34,777
2019 $34,252
2018 $31,589
2017 $32,960
2016 $31,916
2015 $32,983
2014 $36,289
2013 $36,137
2012 $36,105
2011 $40,392
2010 $37,073
2009 $32,924
Novartis AG Quarterly Gross Profit
(Millions of US $)
2022-03-31 $8,958
2021-12-31 $13,484
2021-09-30 $5,491
2021-06-30 $9,380
2021-03-31 $8,655
2020-12-31 $12,566
2020-09-30 $5,032
2020-06-30 $8,193
2020-03-31 $8,986
2019-12-31 $8,724
2019-09-30 $8,706
2019-06-30 $8,618
2019-03-31 $8,204
2018-12-31 $7,859
2018-09-30 $7,923
2018-06-30 $8,095
2018-03-31 $7,712
2017-12-31 $8,675
2017-09-30 $8,369
2017-06-30 $8,236
2017-03-31 $7,680
2016-12-31 $8,117
2016-09-30 $7,973
2016-06-30 $8,228
2016-03-31 $7,598
2015-12-31 $8,255
2015-09-30 $8,097
2015-06-30 $8,409
2015-03-31 $8,222
2014-12-31 $8,938
2014-09-30 $8,879
2014-06-30 $9,571
2014-03-31 $8,901
2013-12-31 $8,564
2013-09-30 $8,780
2013-06-30 $9,193
2013-03-31 $9,600
2012-12-31 $7,281
2012-09-30 $9,464
2012-06-30 $9,931
2012-03-31 $9,429
2011-12-31 $9,878
2011-09-30 $10,246
2011-06-30 $10,504
2011-03-31 $9,764
2010-12-31 $9,940
2010-09-30 $9,158
2010-06-30 $8,715
2010-03-31 $9,260
2009-12-31 $9,478
2009-09-30 $8,187
2009-06-30 $7,918
2009-03-31 $7,341
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $181.123B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $472.758B 18.18
Eli Lilly (LLY) United States $297.134B 35.06
Pfizer (PFE) United States $281.050B 9.80
AbbVie (ABBV) United States $264.095B 11.58
Merck (MRK) United States $232.650B 13.14
GlaxoSmithKline (GSK) United Kingdom $108.662B 12.69
Novo Nordisk (NVO) Denmark $0.000B 32.27